Thursday, 28 May 2020
The News and Media Division of The Insight Partners
Thursday, 14 May 2020 10:00 am

DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS

-DTx was one of 8 grantees selected out of more than 100 academic and company applicants worldwide


DTx Pharma, Inc. (DTx), a privately-held biotechnology company creating novel RNA-based therapeutics to treat the genetic drivers of disease, announced today a new funding award from The Alzheimer's Association® and the Rainwater Charitable Foundation of $400,000 to advance drug discovery research targeting Tau-mediated disorders such as Alzheimer's disease, Progressive Supranuclear Palsy and Frontotemporal Dementia.  The award, along with prior and pending grants, will enable DTx to expand the application of its lipid conjugate technology for the delivery of oligonucleotides as potential treatment for neurodegenerative diseases.

The newly funded program will support the generation and testing of siRNAs designed to reduce the activity of the MSUT2 (mammalian suppressor of Tau) gene, recently characterized as a critical mediator of Tau-induced damage by Dr. Brian Kraemer of the University of Washington and VA Puget Sound in Seattle, WA.  The new MSUT2 program is synergistic with a NIH funded project directly targeting Tau already underway at DTx.  In both cases, siRNA's modified with DTx's novel lipid delivery motif will be delivered to the CNS, for the treatment of neurodegenerative diseases characterized by abnormal accumulation of tau protein in the brain.  Reduction of tau protein expression or reduction of MSUT2 have both been shown to improve behavioral deficits in mouse models of tauopathy, offering attractive therapeutic targets for RNA-based therapies. 

"The Alzheimer's Association and the Rainwater Charitable Foundation created the TPEP program because they recognize the imperative of supporting high risk, high reward approaches for the treatment of neurodegenerative diseases.  As an early stage company, DTx Pharma is excited to receive this award and to have our technology selected for support along with this group of high-quality academic researchers and companies," said Jeff Friedman, MD, PhD and COO of DTx.  "Funding from TPEP will enable us to advance our tauopathy program through preclinical proof of concept studies, and if successful, support rapid advancement of a new therapeutic modality into critical clinical testing. We are grateful for the continued support of partners such as the Alzheimer's Association and Rainwater Charitable Foundation."

Tags Neurodegenerative DTx Pharma RNA CNS Alzheimer's Therapeutics

Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.

Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy